Eric Sagonowsky

Editor

Eric Sagonowsky is an editor with FiercePharma and FierceVaccines. He joined the Fierce staff in November 2014 and covers topics such as drug pricing, biosimilars and product liability litigation.

Stories by Eric Sagonowsky

Sanofi eyes successors for CEO Olivier Brandicourt

by Eric Sagonowsky

Monday, March 18, 2019

Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.

Novo Nordisk fends off Teva's Victoza generic until 2023

by Eric Sagonowsky

Monday, March 18, 2019

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they face Teva's versions of its $2.67B blockbuster Victoza.

AZ's Farxiga cuts risks in heart attack, heart failure patients

by Eric Sagonowsky

Monday, March 18, 2019

After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.

Korea Exchange offices raided in Samsung BioLogics IPO probe

by Eric Sagonowsky

Friday, March 15, 2019

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Revlimid, Eliquis and Eylea top Medicare spending ranks

by Eric Sagonowsky

Friday, March 15, 2019

CMS has rolled out data to show which drugs dominated the most federal spending in 2017 and how their pricing changed from prior years

J&J chalks up another talc loss with $29M jury verdict

by Eric Sagonowsky

Thursday, March 14, 2019

A California jury ordered J&J to pay $29 million to a woman who claimed routine use of J&J’s talc caused her mesothelioma.

Merck limits bladder cancer drug as demand exceeds supply

by Eric Sagonowsky

Thursday, March 14, 2019

Merck has served as the sole supplier of an important drug for years, and now the company says it can't quite keep up.

Lilly chief David Ricks picks up 9% raise to $17.2M

by Eric Sagonowsky

Wednesday, March 13, 2019

Lilly CEO David Ricks, in his second year on the job, hauled in a pay package larger than those of a few of his big pharma peers.

UPDATED: Biopharma breathes 'sigh of relief' with HHS' interim FDA appointment

by Eric Sagonowsky

Tuesday, March 12, 2019

Biopharma hailed the news that Ned Sharpless, now director of the National Cancer Institute, will take the reins at FDA for now

Trump's budget amps up message on familiar drug pricing goals

by Eric Sagonowsky

Tuesday, March 12, 2019

Measures in Trump's 2020 budget aim to incentivize lower list prices, promote competition and more.